Artificial liver support at present and in the future

被引：99

作者：

Onodera K. ^{[1
]}

Sakata H. ^{[1
]}

Yonekawa M. ^{[1
]}

Kawamura A. ^{[1
]}

机构：

[1] Department of Surgery, Sapporo Hokuyu Hospital, Research Institute for Artificial Organs, Transplantation and Gene Therapy, Shiroishi-ku

来源：

Journal of Artificial Organs | 2006年 / 9卷 / 1期

关键词：

Bioartificial liver; Blood purification; Hybrid artificial liver; Liver failure;

D O I：

10.1007/s10047-005-0320-1

中图分类号：

学科分类号：

摘要：

Liver failure is a fatal disease. Liver transplantation is the only established treatment for liver failure; however, donor shortages remain problematic. In the United States and Europe, artificial livers as a bridge to liver transplantation are being considered. In Japan, we have taken a different approach to the treatment of end-stage liver diseases because of the characteristics of the health-care insurance system, regulated by the government. Furthermore, cadaveric liver transplantations are unsuited to the social mores of Japanese culture. Practically speaking, we believe that plasma exchange (PE) and continuous hemodiafiltration (CHDF) are the most effective therapies for the treatment of liver failure, although randomized controlled studies are needed to determine their effects. Overall, we believe that the first line of treatment for liver failure should be PE and CHDF, and the second line should be bioartificial liver support. In the near future, we hope that both gene therapy and regenerative medicine will contribute to the development of a functional artificial liver. © The Japanese Society for Artificial Organs 2006.

引用

页码：17 / 28

页数：11

共 70 条

[1]

Michalopoulos G.K., Defrances M.C., Liver regeneration, Science, 276, pp. 60-66, (1997)

[2]

O'Grady J.G., Gimson A.E., O'Brien C.J., Pucknell A., Hughes R.D., Williams R., Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure, Gastroenterology, 94, pp. 1186-1192, (1988)

[3]

Kolff W.J., The artificial kidney and its effect on the development of other artificial organs, Nat Med, 8, pp. 1063-1065, (2002)

[4]

Kiley J.E., Pender J.C., Welch H.F., Welch C.S., Ammonia intoxication treated by hemodialysis, N Engl J Med, 259, pp. 1156-1161, (1958)

[5]

Opolon P., Rapin J.R., Huguet C., Granger A., Delorme M.L., Boschat M., Sausse A., Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (PAN) hemodialysis (HD), Trans Am Soc Artif Intern Organs, 22, pp. 701-710, (1976)

[6]

Yatzidis H., Oreopoulos D., Triantaphyllidis D., Voudiclari S., Tsaparas N., Gavras C., Stavroulaki A., Treatment of severe barbiturate poisoning, Lancet, 32, pp. 216-217, (1965)

[7]

Chang T.M., Haemoperfusions over microencapsulated adsorbent in a patient with hepatic coma, Lancet, 2, pp. 1371-1372, (1972)

[8]

Gelfand M.C., Knepshield J.H., Cohan S., Ramirez B., Schreiner G.E., Treatment of hepatic coma with hemoperfusion through polyacrylamide hydrogel-coated charcoal, Kidney Int Suppl, (1976)

[9]

Lepore M.J., Martel A.J., Plasmapheresis with plasma exchange in hepatic coma. Methods and results in five patients with acute fulminant hepatic necrosis, Ann Intern Med, 72, pp. 165-174, (1970)

[10]

Yamazaki Z., Inoue N., Hepatic assist device, using membrane plasma separator and dialyzer, Med Prog Technol, 12, pp. 17-24, (1987)

← 1 2 3 4 5 6 7 →